This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events for example heart attack and stroke in people with cardiovascular disease, chronic kidney disease and inflammation. Participants will either get ziltivekimab active medicine or placebo a dummy medicine which has no effect on the body. This is known as the study medicine.
Which treatment participants get is decided by chance. Participants chance of getting ziltivekimab or placebo is the same. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine doctors cannot prescribe. Participants will get the study medicine in a pre filled syringe.
Participants will need to use the pre filled syringe to inject the study medicine into a skinfold once-monthly. The study is expected to last for up to 4 years. Participants will have up to 20 clinic visits. Participants will have blood and urine samples taken at most of the clinic visits.
Participants will have their heart examined using sound waves echocardiography and electrodes electrocardiogram. Women cannot take part if pregnant, breast-feeding or planning to get pregnant during the study period. Evidence of atherosclerotic cardiovascular disease ASCVD by one or more of thefollowing: a Coronary heart disease defined as at least one of the following: i.
Documentedhistory of MI ii. Prior coronary revascularisation procedure iii. Prior stroke of atherosclerotic origin ii. Priorcarotid artery revascularisation procedure iii. Intermittent claudication with an ankle-brachial index ABI below orequal to 0.
